Radioligand Therapy Market is set to grow rapidly, rising from $2.41B in 2024 to $15.80B by 2033, driven by advanced cancer treatments and targeted therapies. The U.S. Radioligand Therapy Market is ...

SAR-Bombesin targets the gastrin-releasing peptide receptor (GRPR), a promising pan-cancer target expressed in a number of ...

A review of 22 trials led the American Society of Clinical Oncology (ASCO) to issue updates to its mCRPC systemic therapy ...

New findings suggest that a PSA level of 0.2 ng/mL or greater can predict a poor prognosis and indicate a possible need for ...

The American Cancer Society estimates that more than 313,780 cases of prostate cancer will be diagnosed in the United States ...

News broke recently that former President Joe Biden has been diagnosed with an aggressive form of metastatic prostate cancer. The disease, which has now spread to his bones, is life-threatening ...

Adding niraparib to AAP and ADT improved rPFS in mCSPC patients with HRR mutations in the phase 3 AMPLITUDE trial.

The FDA has approved Nubeqa (darolutamide), an androgen receptor inhibitor, for the treatment of mCSPC in adults.

FN Media Group News Commentary - The global oncology market is undergoing rapid growth, mainly due to the increasing number of cancer cases around the world. The World Health Organization estimates ...

A top doctor to Presidents Barack Obama and Donald Trump told the Washington Free Beacon that the prognosis for former ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) today announces that its next-generation PSMA-PET imaging 1 agent for prostate cancer, Gozellix® (kit for the preparation ...